1 Cathie Wood Stock That Could Double Your Money
Cathie Wood's Ark Investment Management has deemed CRISPR/Cas 9 genome editing as "biotech's breakthrough of the century." Back in 2018, Ark identified this gene-editing tool as a potential $2 trillion-a-year opportunity, thanks to its potential to disrupt the treatment of 10,000 monogenic human diseases, aquaculture, and medical diagnostics.
After a dramatic sell-off in CRISPR/Cas 9 gene-editing stocks during the 2022 bear market, Wood's flagship fund has been steadily buying shares of Intellia Therapeutics (NASDAQ: NTLA) in 2023. Intellia is the second most advanced CRISPR/Cas9 player among the space's small contingent of publicly traded companies.
Image Source: Getty Images.
Source Fool.com
Intellia Therapeutics Inc Aktie
19,39 €
4,36 %
Mehrere Buy-Einschätzungen dominieren bei Intellia Therapeutics Inc ohne Sell-Gegenstimmen.
Bei einem durchschnittlichen Kursziel von 60 € für Intellia Therapeutics Inc, wäre dies mehr als eine Verdopplung des aktuellen Kurses von 19.39 €.
